http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

PpP: You were right about the new holdings. Have noted that Aviva, via their subsidiary Morley, have joined the stake holders, taking up 10% of APH. I'm glad that us ordinary mortals were able to clamber aboard ahead of the action.
sd.

squidd I knew something was going on then and its good news that comes through,will be adding more in the coming months.

PpP: I slept soundly yesterday morning as ULT climbed 50% until wakened by a call from a day trader friend, who urged me to sell. But after we talked about the various scenarios for the global roll out of ULT's CBT and a possible reaction from beleaguered pharmas, defending their tranquilliser pills, he agreed that I would have to buy back pdq, so I'm still in.
I hope that somewhere along the line people will recognise that APH's Posidorm is also a type of traquilliser, but being the body's own produce, is unlikely to have side effects.
sd.

squidd ULT is still up and down but if they can come up with the goods then it should be a lot more up than down in future.

Very interested in BOI at the moment, been slowely adding and I think this will wake up (no Posiderm for BOI to sleep on) very soon. Could give some strong gains through this year and next.

PpP: I sold my APH earlier in the week, at a healthy profit, in order to top up my front runners CSB, AEX and of course ULT. So, very grateful for your hard work on APH which has helped fill my pockets and hoping you are with us on ULT.
sd.

squidd, yes I have taken a small go with ULT and its moving ups so thanks for the nod on ULT. Am taking a closer look at CSB and AEX.

One of my small holdings GRL went up today on very good news, it might have some more go in it too.

Alliance Pharma PLC
11 October 2005
For Immediate Release 11 October 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')
Notification of Interim Results

On behalf of our client Alliance Pharma plc (AIM: APH), the emerging speciality
pharmaceutical company, we notify that they will be reporting their Interims
Results for the six months ended 31 August, on Thursday 3 November, 2005.

For further information:
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.
Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.
Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC
03 November 2005

For Immediate Release 3 November 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')

Uniflu UK disposal raises 500,000

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has divested Uniflu, its cold and flu product,
for a one-off payment of 500,000.

Uniflu was acquired as part of the acquisition of Forceval, a prescription based multi-vitamin for clinical malnutrition, in November 2004. The UK business for Uniflu, as a consumer healthcare product, is non-core to Alliance, therefore the company has taken the decision to divest the brand to G R Lane Health Products Ltd based in Gloucester, UK, for a one-off payment of 500,000. Alliance retains its Uniflu export business, with annual sales of 419,000 which is managed via distributors.

Uniflu's presence in the UK market is underdeveloped compared with its position
in several other markets, particularly Lebanon where it is market leader in the
cold and flu segment.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:

'We have taken the decision to divest Uniflu for a one-off payment as the
product is non-core to the Alliance Pharma business. We continue to retain the
export sales on Uniflu as that market is further developed and offers more value going forward.'

For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Interim Results for the six month period ended 31 Augst 2005

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its interim results for the half year ended 31 August
2005.

Financial Highlights

Sales up 35.5% to 7.5m
Profit after tax, on an IFRS basis was 385K
Gross margin improvement of 53.6%
Operating cashflow remains strong at 1.6m
Basic earnings per share of 0.26p
Financial year changing to December 31st - commencing December 2005

Operational Highlights

Phase III clinical trials on Isprelor(TM), (induction of labour)

- trials expected to complete the middle of 2006

Phase III trials on Posidorm(TM), (melatonin for sleeping disorders),

- on track for introduction in 2007

Selective acquisition of reputable prescription brands under discussion

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said:
'Our interim results for the 6 months to August 2005 represent another period of good, on-target, performance from the current business with solid progress also being made on the development projects. Significant progress has also been made in building and strengthening the managerial team...... We look forward to the next half year with continued optimism.'


Diluted EPS 0.46p

Anyone know why it has fallen 9% today?

Its probably just the December syndrome, end of year, and MM's want to finish the year at evens on as many stocks as they can, so this is why in December on MM controlled stocks, there can be wild price swings up and down as year end positons are cleared and stated.

Alliance Pharma PLC
23 March 2006




FOR IMMEDIATE RELEASE 23 MARCH 2006


ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Preliminary Results for the 10 month period ended 31 December 2005

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce its preliminary results for the ten month period ended 31
December 2005. The results cover a 10 month period owing to a change to the
Company's year end to 31 December 2005, bringing the Company's year end into
line with that of its peers.

Financial Highlights



Sales for the 10 month period of 12.28 million (12 months to 31
December 2004: 11.83m)

Sales growth on an annualised basis of 24.6%

Gross margin improvement to 54.3% (2004: 52.4%)

Operating cashflow remains strong at 1.79 million (2004: 1.57m)

Earnings before interest and tax of 2.17 million (2004: 2.26m)

Pre-tax profit of 0.66 million (2004: 0.41m)

Operational Highlights

Launch of Dental Products division and promotion of Periostat for
periodontitis

Launch of International Division for marketing of Periostat and
Forceval

Start of Phase III clinical trials of Posidorm for sleep disorders

Acquisition of Hydromol dermatology range post the year end

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said: '
During the period under review, Alliance has moved closer to its goal of
delivering substantial and growing revenue streams from brands both acquired and
developed in-house. All our efforts will continue to be directed towards
achieving this goal.'

Recent buying explained, just been tipped today as a long term buy by uk-analyst.com

Alliance Pharma PLC
10 May 2006
ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Placing to raise 2.5 million

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has conditionally placed 14,705,883 new ordinary shares of
1p each in the capital of the Company ('Ordinary Shares') at a price of 17p per
share, raising a total of 2.5 million (before expenses) for the Company.
Application has been made to AIM for the new shares to be admitted to trading,
which is expected to commence on 15 May 2006.

The proceeds of the placing will be used for general corporate purposes.

John Dawson, Alliance Pharma's Chief Executive, commented:

'I am delighted by the support of new and existing investors in this
fundraising, the proceeds of which will provide additional finance as the
Company moves closer to the regulatory filing of key pipeline products including
Posidorm for sleep disorders.'

The placing has been undertaken by Numis Securities Limited ('Numis') and is
conditional on the placing agreement between Numis and the Company becoming
unconditional and not being terminated on or before 15 May 2006 (or such later
date as Numis and the Company may agree, being not later than 30 May 2006). The new Ordinary Shares will rank pari passu in all respects with the existing
Ordinary Shares in issue.

For further information:

Alliance Pharma plc +44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications +44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and international pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC 18 May 2006

ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Further expansion of skincare portfolio through bolt-on acquisition
of Caraderm Limited

Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleased
to announce that it has agreed to acquire Caraderm Limited ('Caraderm'), a
Northern Ireland company whose key asset is Dermamist, a dermatological spray
for dry skin conditions.

Based on 2005 volumes, Dermamist will add annualised sales of 108,000 and adds
a further product to Alliance's growing dermatology portfolio.

Alliance is paying 260,000 in cash for the entire share capital of Caraderm,
under a transaction in which staff will not be transferred to Alliance.

John Dawson, Alliance Pharma's Chief Executive, commented: 'This latest
acquisition delivers a further product to our dermatology portfolio. We gained
critical mass in dermatology earlier this year through the acquisition of the
Hydromol range and we look forward to the continuing success of our skincare
franchise.'

For further information:

Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 30 branded pharmaceutical products and continues to explore
opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.

Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for the induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

PP

Price is heading in wrong direction...any views?

Free research report to read (its free to register and therefore read it) at

http://www.objectivecapital.co.uk/objectiveresearch.asp?


Just Released August 2006.

Not a lot of interest here, anymore. - and the sp seems to be sliding, - not helped by "further research trials" needed by "EuroMedical" or whatever Authority.
I'm not sure about their China connection either; it might be a bold move, or a can of worms - what do others think? (Presently I don't hold and I'd like to know their cash-position, if anyone acan say for certain).
EDIT 29May: Have bought a few as I suspect this is "the bottom" and I like the way Management is open, etc. (so far).

Sudden 25% rise! ( 10.5p mid.)
Looks like I might break-even - - - and today I looked at their products - quite nice range.....

Maybe this signals a takeover, it's a rapid rise for sure.

Proactive Investors One2One Forums

The directors of Netplay TV Plc (AIM: NPT), Synchronica plc (AIM: SYNC) and Alliance Pharma plc (AIM: APH) will be presenting:

Wednesday the 22nd July 2009

Venue : Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 7:30pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.


Register Here : http://www.proactiveinvestors.co.uk/eventregistration.php


These are really good events set in a wonderful location, and are an excellent chance to meet the CEo's of these companies and have an informal chat over free wine and canapafter the formal presentations are complete.

The evenings have a good balance of city professionals, and private investors.

If you have any problems registering or queries please email : action@proactiveinvestors.com


Nearest tube stations are Green Park (5 minutes walk) and Bond Street (7 mins)